The Role of Magnetized Water in Improving Dietary Supplements and Their Effect on the Life Performance of Honey Bee Colonies Apis mellifera L.

This study is conducted by using strain of hybrid local honeybees Apis mellifera L. from 20th of April to 20th of July 2016 in Wassit Provence / Al-kut city. This study aims at discovering the effect of magnetic food on the activity of honey bee colonies and improve their production in the spring and summer seasons . Three magnetic power are treated in this study (1000, 2000, 3000) Gauss. The results show that honeybee colonies fed with magnetized food are significantly higher in both open and closed incubation brood, and are higher in density compared to natural feeding. For the open brood area, the magnetic food treatments G 2000 and G3000 exceed 3024.57 and 3382.67 cm2 respectively. The lowest comparative treatment is 2772.81 cm2 / hive, the treatment G 3000 exceed the treatments G 1000 and 2000 G and the treated G 1000 as an average brood area open is 2908.75 cm2 / hive, Similarly, closed brood area for workers the magnetic food treatments 2000 G and G3000 are 2792.12 and 3205.91 cm2 / hive respectively, while the comparison treatment is 2533.14 cm2 / hive, and the treatment G 3000 exceed the treatments G 1000 and G 2000 Where treatment 1000 G give the average closed brood area of 2652.78 cm2 / hive. Density is the highest for G 2000 and G 3000 are 13.17 and 14.12 frame / hive respectively, while the lowest comparison treatment is 10.59 frame / hive.

Organic Content in the Sediments of Tigris and Diyala Rivers, south of Baghdad, and its Relationship with some Environmental factors, Benthic Invertebrates Groups and Values of Diversity Indices

This study was conducted to detect the relationship between organic content in the sediment of Rivers Tigris and Diyala, at two locations south of Baghdad, with some environmental factors and the benthic invertebrates and values of diversity indices. Monthly samples collected from the area for the period November 2007 to October 2008. Results showed differences in the physical and chemical characteristics of the two sites, Where the annual average in Tigris and Diyala were respectively for: water temperature (19, 20) C°, pH (8, 8), dissolved oxygen (4, 8) mg / l , Biochemical oxygen Demand BOD5 (3,44 ) mg/l, TDS (632,1585) mg / l, TSS (42, 44) mg / l, turbidity (28,74) NTU, and total hardness as CaCO3 (485,823) mg / l ,Sulfate as SO4 ?(183,366),And finally nitrate as NO3 (4, 6) mg / l. Significant differences were found in the organic matter content as a percentage in the sediments of Diyala River for most months of the study period. Annual average of the percentage of organic matter in the samples of Tigris and Diyala Rivers were respectively: 0.7425 and 1.1375. The benthic groups included variety of benthic organisms; insects, Oligochaetes, Mollusks, and Crustaceans. Highest population density in Tigris River was for insects 31493 individual / m2, Mollusks 23177 individual / m2, Oligochaetes 10774 individual / m2, and Crusteacea 176 individual / m2 which were confined to Tigris River. In Diyala River highest population density was 9908, 18046, 82649 individual / m2 for Mollusks, Insects and Oligochaetes respectively. Values of diversity indices of benthic invertebrates were highest for species richness and equitability in Diyala River respectively, 18.6 and 8.29 in February, while lower values for species richness and equitability in Tigris River were respectively 1.56 and 3.31 in the same month. Most groups of invertebrate have shown significant positive and negative relationships with the physical and chemical and organic characteristics in both Rivers

Hydrogen bonds between methanol and the light liquid olefins 1-pentene and 1-hexene: From novel application to fundamental science

We have recently developed a new extraction process for significantly reducing the olefin content in commercial FCC gasoline. To gain insights into the origins of this process , we have investigated the dissolution of the light liquid olefins 1-pentene and 1-hexene in methanol through computer modelling together with NMR spectroscopy. We find two important hydrogen bonding modes for methanol olefin interactions – namely, O-H···π and C-H···O

In vitro colonization of date palm plants by Rhizophagus irregularis during the rooting stage

The use of in vitro culture of date palm plants Phoenix dactylifera, associated with arbuscular mycorrhizal (AM) fungi is a novel approach for the production of bio-fortified plants that are free of pathogens. Here, we report, for the first time, the in vitro mycorrhization of in vitro date palm plants using the AM fungus Rhizophagus irregularis MUCL 41833. Date Plants were used in an in vitro cultured system that consisted of a root compartment (RC) containing germinated seeds of Barrel Clover, Medicago truncatula, and spores of Rhizophagus irregularis as a mycorrhizal donor, and a hyphal compartment (HC) with a barrier separating the RC from the HC. In vitro cultured date palm plants, at the two-leaf stage, were placed in the HC section of the culture plate that after 6 weeks contained an active growing extraradical mycelium network of the fungus. Roots of the date palm became colonized after 10 weeks and hyphae, vesicles, spores and arbuscules, were detected. No differences were noticed in above-ground parameters between mycorrhized and non-mycorrhized plants, in which there was no fungus in the HC. However, the total root length was significantly higher and secondary and tertiary roots were significantly more numerous, in the mycorrhized plants. It is hypothesized that these differences are related to stimulating molecules released by the profuse extraradical mycelium of the fungus growing in close contact with the palm root system. Root colonization percentages were of the same order as those reported in pots cultures of the date palm plants. This work opens the door for the large-scale in vitro mycorrhization of date palm plants, potentially better adapted to acclimatization phase and possibly to the field

Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial

Background: Intravenous ferric carboxymaltose has been shown to improve symptoms and quality of life in patients with chronic heart failure and iron deficiency. We aimed to evaluate the effect of ferric carboxymaltose, compared with placebo, on outcomes in patients who were stabilised after an episode of acute heart failure. Methods: AFFIRM-AHF was a multicentre, double-blind, randomised trial done at 121 sites in Europe, South America, and Singapore. Eligible patients were aged 18 years or older, were hospitalised for acute heart failure with concomitant iron deficiency (defined as ferritin <100 μg/L, or 100–299 μg/L with transferrin saturation <20%), and had a left ventricular ejection fraction of less than 50%. Before hospital discharge, participants were randomly assigned (1:1) to receive intravenous ferric carboxymaltose or placebo for up to 24 weeks, dosed according to the extent of iron deficiency. To maintain masking of patients and study personnel, treatments were administered in black syringes by personnel not involved in any study assessments. The primary outcome was a composite of total hospitalisations for heart failure and cardiovascular death up to 52 weeks after randomisation, analysed in all patients who received at least one dose of study treatment and had at least one post-randomisation data point. Secondary outcomes were the composite of total cardiovascular hospitalisations and cardiovascular death; cardiovascular death; total heart failure hospitalisations; time to first heart failure hospitalisation or cardiovascular death; and days lost due to heart failure hospitalisations or cardiovascular death, all evaluated up to 52 weeks after randomisation. Safety was assessed in all patients for whom study treatment was started. A pre-COVID-19 sensitivity analysis on the primary and secondary outcomes was prespecified. This study is registered with ClinicalTrials.gov, NCT02937454, and has now been completed. Findings: Between March 21, 2017, and July 30, 2019, 1525 patients were screened, of whom 1132 patients were randomly assigned to study groups. Study treatment was started in 1110 patients, and 1108 (558 in the carboxymaltose group and 550 in the placebo group) had at least one post-randomisation value. 293 primary events (57·2 per 100 patient-years) occurred in the ferric carboxymaltose group and 372 (72·5 per 100 patient-years) occurred in the placebo group (rate ratio [RR] 0·79, 95% CI 0·62–1·01, p=0·059). 370 total cardiovascular hospitalisations and cardiovascular deaths occurred in the ferric carboxymaltose group and 451 occurred in the placebo group (RR 0·80, 95% CI 0·64–1·00, p=0·050). There was no difference in cardiovascular death between the two groups (77 [14%] of 558 in the ferric carboxymaltose group vs 78 [14%] in the placebo group; hazard ratio [HR] 0·96, 95% CI 0·70–1·32, p=0·81). 217 total heart failure hospitalisations occurred in the ferric carboxymaltose group and 294 occurred in the placebo group (RR 0·74; 95% CI 0·58–0·94, p=0·013). The composite of first heart failure hospitalisation or cardiovascular death occurred in 181 (32%) patients in the ferric carboxymaltose group and 209 (38%) in the placebo group (HR 0·80, 95% CI 0·66–0·98, p=0·030). Fewer days were lost due to heart failure hospitalisations and cardiovascular death for patients assigned to ferric carboxymaltose compared with placebo (369 days per 100 patient-years vs 548 days per 100 patient-years; RR 0·67, 95% CI 0·47–0·97, p=0·035). Serious adverse events occurred in 250 (45%) of 559 patients in the ferric carboxymaltose group and 282 (51%) of 551 patients in the placebo group. Interpretation: In patients with iron deficiency, a left ventricular ejection fraction of less than 50%, and who were stabilised after an episode of acute heart failure, treatment with ferric carboxymaltose was safe and reduced the risk of heart failure hospitalisations, with no apparent effect on the risk of cardiovascular death. Funding: Vifor Pharma